ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 700,72
0,50%
Dow Jones
39 112,16
-0,76%
DAX
18 354,38
1,06%
Brent Oil
84,475
0,34%
Bitcoin
61 704,64
-0,17%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Royaume-Uni
  5. LSE
  6. Roche Holding Ag (0QQ6)

  7. Roche Holding Ag (0QQ6) Actualités

0QQ6

Roche (0QQ6)

Roche Holding Ag
De:
Trier par:
 Showing the most relevant articles for your search:LSE:0QQ6
DateHeureSourceTitreSymboleSociété
25/06/202407h00UK RegulatoryRoche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosisLSE:0QQ6Roche Holding Ag
24/06/202407h00UK RegulatoryRoche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratoriesLSE:0QQ6Roche Holding Ag
20/06/202407h00UK RegulatoryRoche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphomaLSE:0QQ6Roche Holding Ag
15/06/202416h00UK RegulatoryRoche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphomaLSE:0QQ6Roche Holding Ag
10/06/202407h05UK RegulatoryRoche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use AuthorizationLSE:0QQ6Roche Holding Ag
10/06/202407h00UK RegulatoryEuropean Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancerLSE:0QQ6Roche Holding Ag
07/06/202416h40UK RegulatoryFive-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walkLSE:0QQ6Roche Holding Ag
29/05/202407h00UK RegulatoryFDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutationLSE:0QQ6Roche Holding Ag
27/05/202407h00UK RegulatoryWechsel in der erweiterten Konzernleitung von RocheLSE:0QQ6Roche Holding Ag
27/05/202407h00UK RegulatoryChanges to the Roche Enlarged Corporate Executive CommitteeLSE:0QQ6Roche Holding Ag
22/05/202407h00UK RegulatoryRoche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular riskLSE:0QQ6Roche Holding Ag
21/05/202407h00UK RegulatoryFDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutationLSE:0QQ6Roche Holding Ag
16/05/202407h00UK Regulatory[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesityLSE:0QQ6Roche Holding Ag
15/05/202407h00UK RegulatoryRoche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancerLSE:0QQ6Roche Holding Ag
24/04/202407h00UK Regulatory[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19LSE:0QQ6Roche Holding Ag
24/04/202407h00UK Regulatory[Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-ProdukteLSE:0QQ6Roche Holding Ag
19/04/202407h00UK RegulatoryFDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancerLSE:0QQ6Roche Holding Ag
17/04/202408h00UK RegulatoryRoche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MSLSE:0QQ6Roche Holding Ag
15/04/202407h00UK Regulatory[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO studyLSE:0QQ6Roche Holding Ag
11/04/202407h00UK RegulatoryRoche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosisLSE:0QQ6Roche Holding Ag
26/03/202417h45UK RegulatoryRoche receives FDA approval for the first molecular test to screen for malaria in blood donorsLSE:0QQ6Roche Holding Ag
12/03/202413h30UK RegulatoryRoche Annual General Meeting 2024LSE:0QQ6Roche Holding Ag
12/03/202413h30UK RegulatoryRoche Generalversammlung 2024LSE:0QQ6Roche Holding Ag
12/03/202413h30UK RegulatoryAssemblée générale 2024 de RocheLSE:0QQ6Roche Holding Ag
05/03/202413h30UK RegulatoryRoche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of careLSE:0QQ6Roche Holding Ag
25/02/202420h00UK RegulatoryNew England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergiesLSE:0QQ6Roche Holding Ag
16/02/202417h24UK RegulatoryFDA approves Xolair as first and only medicine for children and adults with one or more food allergiesLSE:0QQ6Roche Holding Ag
01/02/202407h03UK RegulatoryNew long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)LSE:0QQ6Roche Holding Ag
01/02/202407h00UK Regulatory[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche übertrifft Guidance für 2023 und erzielt trotz stark rückläufigem COVID-19-Umsatz Verkaufswachstum von 1% (CER)LSE:0QQ6Roche Holding Ag
01/02/202407h00UK Regulatory[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales declineLSE:0QQ6Roche Holding Ag
 Showing the most relevant articles for your search:LSE:0QQ6

Dernières Valeurs Consultées

LSE
MF44
Roy.bk.can.23
USOTC
THNUY
Thanachart Capital Public (PK)
EU
AXAIF
Axa Banque null
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés